Yuyang Zhang

Prof. Yuyang Zhang

Shenyang Pharmaceutical University in China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KMKe Ma
Ke Ma
YLYali Lu
Yali Lu
SJShanshan Jiang
Shanshan Jiang
JTJiangong Tang
Jiangong Tang
XLXin Li
Xin Li
YZYuyang Zhang
Yuyang Zhang
Background: Recently, immune checkpoint inhibitors (ICIs) have been proved one of the most promising anti-cancer therapy, series clinical trials have confirmed their efficacy. But they are also associated with distinctive set of toxic effects, which are recognized as immune-related adverse events. Among those immune-related adverse events, pneumonitis is rare, but it is often clinically serious and potentially life-threatening. Although many clinical trial results of PD-1/PD-L1 inhibitors had been reported incidence of pneumonitis, the knowledge based on the individual cohort data from each clinical trial is limited. So we conducted a meta-analysis of trials of PD-1/PD-L1 inhibitors in patients with advanced cancer and compared relative risk and incidence among different tumor types and therapeutic regimens. Such an analysis may provide important knowledge of this rare but clinically significant and potentially serious immune-related adverse event. Methods: Electronic databases were used to search eligible literatures, include randomized controlled trials (RCTs) comparing immune checkpoint inhibitors vs. standard therapies. All-grade (1–4) or high-grade (3–4) pneumonitis events were extracted. The summary relative risk, summary incidence, and 95% confidence intervals were calculated. Results: The incidence of all-grade and high-grade pneumonitis in non-small cell lung cancer (NSCLC) was significantly higher compared with other tumor types, such as Melanoma, urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC) (3.1% vs. 2.0%; p = 0.02, 1.4% vs. 0.6%; p = 0.03). The risk of all-grade pneumonitis was obtained from all patients in both experimental arm and control arm. Treatment with immune checkpoint inhibitors targeting PD-1/PD-L1 did significantly increase the risk of all-grade and high-grade pneumonitis compared with controls (fixed effects, RR: 4.70; 95% CI: 2.81–7.85; p < 0.00001, RR: 3.33; 95% CI: 1.68–6.59; p = 0.0006). Conclusion: The incidence of immune checkpoint inhibitors related pneumonitis was higher in NSCLC than other tumor types. Patients treated with immune checkpoint inhibitor in experiment arms are more likely to experience any grade pneumonitis than control arms. These findings suggest that clinician need to draw more attention on this rare but serious adverse event.

24 September 2014 in International Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
YRYanxin Ren
Yanxin Ren
BWBing Wei
Bing Wei
XSXirui Song
Xirui Song
NANan An
Nan An
YZYiying Zhou
Yiying Zhou
YZYuyang Zhang
Yuyang Zhang
Free radicals and oxidative stress play key roles in cerebral ischemic pathogenesis and represent pharmacological targets for treatment. Edaravone (Edv), one of antioxidant agents that have been used in acute ischemic stroke in both clinical settings and animal experiments, exerts neuroprotective effect on ischemic injured brains. This review is aimed to elaborate the latest molecular mechanisms of the neuroprotection of Edv on cerebral ischemia and provide reasonable evidence in its clinical application. It is found that Edv has neuroprotective influence on cerebral ischemia, which is closely related to the facets of scavenging reactive oxygen species (ROS), hydroxyl radical (ċOH) and reactive nitrogen species (RNS). And it is a good antioxidant agent that can be safely used in the treatment of cerebral ischemia and chronic neurodegenerative disorders as well as other ischemia/reperfusion (I/R)-related diseases. The combination of Edv with thrombolytic therapy also can be applied in clinical settings and will be greatly beneficial to patients with stroke.

1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
LZLan Zhang
Lan Zhang
LYLinglong Yang
Linglong Yang
XZXiaofei Zhang
Xiaofei Zhang
LJLi Jiaqi
Li Jiaqi
LFLinlin Fan
Linlin Fan
SMShirui Mao
Shirui Mao

1 June 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SLShiyi Lin
Shiyi Lin
XLXin Li
Xin Li
JZJiabei Zhang
Jiabei Zhang
YZYuyang Zhang
Yuyang Zhang

1 September 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
JLJiaqi Li
Jiaqi Li
HZHuangliang Zheng
Huangliang Zheng
LQLu Qin
Lu Qin
EXEn-Yu Xu
En-Yu Xu
LYLinglong Yang
Linglong Yang
SMShirui Mao
Shirui Mao

1 October 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JLJiaqi Li
Jiaqi Li
HZHuangliang Zheng
Huangliang Zheng
XLXiaoran Li
Xiaoran Li
JSJian Su
Jian Su
LQLu Qin
Lu Qin
SMShirui Mao
Shirui Mao